… RNAtherapy Find out how RNAtherapy works, how it differs from … underlying cause of the disease. Watch: How do ProQR's RNA therapies work? A short introduction to RNA therapies Why focus on RNA therapies? Why focus on RNA therapies? RNA therapies can …
… medicines” The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the … Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology … Biology/Molecular Biology. What is Klein’s connection to RNA therapeutics? “At the end of the 80s, I wrote my master’s …
… Board with Leaders in Inherited Retinal Disease and RNATherapy LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today …
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board.
… biotech company advancing our proprietary Axiomer RNA-editing platform technology. We are ProQR We are ProQR We … company dedicated to changing lives by developing RNA therapies for severe rare and common diseases. We focus … and Cambridge, Massachusetts, USA. Learn more about RNAtherapy and our Axiomer technology . We are on a mission We …
… Always excited about RNA therapies He is one of the founders of ProQR, but even … as they say. Gerard Platenburg What made you pursue RNAtherapy as a potential treatment for these diseases? “Well, …
